OBJECTIVE： To systematically evaluate the effects of topical application of Prostaglandin eye drops on corneal thickness in patients with primary open-angle glaucoma， and to provide evidence-based reference in clinic. METHODS： Retrieved from Cochrane library， PubMed， EMbase， Medline， CNKI， VIP， CBM and Wanfang database， randomized controlled trials （RCTs） about the effects of Prostaglandin eye drops （trial group） and conventional drug or placebo （control group） on corneal thickness were collected. After data extraction and quality evaluation with Cochrane Systematic Reviewer Manual 5.2， Meta-analysis was performed by using Rev Man 5.3 software. RESULTS： A total of 6 RCTs were included， involving 527 patients. The results of Meta-analysis showed that there was no statistical significance in central corneal thickness [MD＝－13.63，95％CI（－28.50，1.23）， P＝0.07]， apical cornea thickness [MD＝－7.53，95％CI（－19.46，4.40）， P＝0.22]， thinnest corneal thickness [MD＝－5.87，95％CI（－17.69，5.95）， P＝0.33] or intraocular pressure [MD＝－5.44，95％CI（－14.90，4.02）， P＝0.26] between 2 groups. CONCLUSIONS： Prostaglandin eye drops have no significant effect on corneal thickness in patients with primary open-angle glaucoma.